Abstract

Portal hypertension (PHT) is a common and serious clinical syndrome often associated with chronic liver diseases. Portal hypertension may be defined as portal pressure gradients of 12 mmHg or more in the veins of the portal system caused by obstruction in the liver from intrahepatic or extrahepatic portal venous compression or occlusion (often associated with chronic liver disease), causing enlargement of the spleen and collateral veins. In the western world, hepatic cirrhosis related to chronic hepatitis C and B and alcoholic cirrhosis are the conventional rationale for the development portal hypertension. Besides cirrhosis, a number of disorders collectively called as noncirrhotic portal hypertension (NCPH) can also result in portal hypertension. Evaluation of non-cirrhotic portal hypertension is more difficult than cirrhotic portal hypertension, both from clinical and pathological perspectives.

Keywords: Animal Models · Non Cirrhotic Portal Hypertension

References

  1. 1.Ariosto F, Riggio O, Cantafora A, Colucci S, Gaudio E, Mechelli C et al. Carbon tetrachloride-induced experimental cirrhosis in the rat: a reappraisal of the model. Eur Surg Res 1989;21:280–6.
  2. 2.Burgener FA, Gutierrez OH, Logsdon GA. Angiographic, hemodynamic, and histologic evaluation of portal hypertension and periportal fibrosis induced in the dog by intraportal polyvinyl alcohol injections. Radiology 1982; 143: 379-385.
  3. 3.Cahill PA, Foster C, Redmond EM, Gingalewski C, Wu Y, Sitzmann JV. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995; 22: 598-6
  4. 4.Castaneda B, Debernardi-Venon W, Bandi JC, Andreu V, Perez-del-Pulgar S, Moitinho E, Pizcueta P, Bosch J. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000; 31: 581-586
  5. 5.Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portalhypertensive rats. Hepatology 1992; 15: 323-328
  6. 6.Colombato LA, Robin M, PomierLayrargues G, Huet PM. Animal models of portal hypertension. In: Holstege A, Hahn EG, Scholmerich J, editors. Portal Hypertension – Proceedings of the 79th Falk Symposium. Germany: Kluwer Academic Publishers, 1995.pp. 3–14.
  7. 7.Dashti H, Jeppsson B, Hägerstrand I, Hultberg B, Srinivas U, Abdulla M et al. Thioacetamideand carbon tetrachlorideinduced liver cirrhosis. Eur Surg Res 1989;21:83–91.
  8. 8.Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, Puri P, Mitra SK, Suri S. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17 (1):6-16. Non-Cirrhotic Portal Hypertension, Moattar R Rizvi MAJMAAH J. HEALTH SCIENCES, 2013 – Vol. 1, No. 1
  9. 9.Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portalsystemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-894
  10. 10.Franco D, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction: effect of bile diversion on portal pressure in the rat. Arch Surg 1979;114:1064–7.
  11. 11.Gaisford WD, Zuidema GD. Nutritional Laennec’s cirrhosis in the macaca mulatto monkey. J Surg Res, 1965;5: 220-235.
  12. 12.Guha Mazumder DN, Chakraborty AK, Ghosh A, et al. Chronic arsenic toxicity from drinking tubewell water in rural west Bengal. Bull Wld Health Org 1988;66:499–
  13. 13.Guha Mazumder DN, Das Gupta J, Santra A, et al. Noncancer effects of chronic arsenicosis with special reference to liver damage. In: Arsenic Exposure and Health Effects. Abernathy CO, Calderon RL, Chappell WR, eds., London: Chapman & Hall 1997;112–123.
  14. 14.Huet PM, Guillaume E, Cote J, Legare A, Lavoie P, Viallet A. Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication. Gastroenterology 1975; May;68(5 Pt 1):1270-7.
  15. 15.Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1074-G1081
  16. 16.Kathayat R, Pandey GK, Malhotra V, Omanwar S, Sharma BK, Sarin SK. Rabbit model of non-cirrhotic portal fibrosis with repeated immunosensitization by rabbit splenic extract. J Gastroenterol Hepatol. 2002 Dec;17(12):1312-6.
  17. 17.Kaza RM, Sharma BK, Sarin SK, Malhotra V, Kumar S, Rana BS. Evaluation of three surgical techniques for developing an animal model of non-cirrhotic portal fibrosis. In: Animal Models of Portal hypertension, 1988 pg73-79.
  18. 18.Komeichi H, Katsuta Y, Aramaki T, Okumura H. A new experimental animal model of portal hypertension. Intrahepatic 69 REVIEW ARTICLE MAJMAAH J. HEALTH SCIENCES, 2013 – Vol. 1, No. 1 portal obstruction by injecting DEAEcross-linked dextran microspheres into the portal vein in the rabbit. Nippon Ika Daigaku Zasshi. 1991 Jun;58(3):273-84.
  19. 19.Kono K, Ohnishi K, Omata M, Saito M, Nakayama T, Hatano H, Nakajima Y, Sugita S, Okuda K. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology. 1988 Mar;94(3):787-96.
  20. 20.Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305–11.
  21. 21.Kunio Okuda Non-cirrhotic portal hypertension: Why is it so common in India? Journal of Gastroenterology and Hepatology. 2002 17, 1–5.
  22. 22.Lee FY, Groszmann RJ. Experimental models in the investigation of portal hypertension. Ascites Ren Dysfunct Liv Dis Pathog Diagn Treat 1999;1:365–78.
  23. 23.Li X, Benjamin IS, Alexander B. Reproducible production of thioacetamideinduced macronodular cirrhosis in the rat with no mortality. J Hepatol 2002;36:488–
  24. 24.Miyakawa H, Iida S, Leo MA, Greenstein RJ, Zimmon DS, Lieber CS. Pathogenesis of precirrhotic portal hypertension in alcohol-fed baboons. 1985. Gastroenterology 88: 143-150.
  25. 25.Myking AO, Halvorsen JF. Two-stage occlusion of the portal vein in the rat: Survival related to weight variation and the interval between partial and total occlusion. Eur Surg Res 1975;7: 366-374.
  26. 26.Narang AP. Arsenicosis in India. J Clinic Toxicol 1987; 25 (4): 287-295
  27. 27.Omanwar S, Rizvi MR, Kathayat R, Sharma BK, Pandey GK, Alam MA, Pandey GK, Malhotra V, Sarin SK.A rabbit model of non-cirrhotic portal hypertension by repeated injections of E.coli through indwelling cannulation of the gastrosplenic vein. Hepatobiliary Pancreat Dis Int. 2004; 3(3):417-22.
  28. 28.Petermann H, Vogl S, Schulze E, Dargel R. Chronic liver injury alters basal and stimulated nitric oxide production and 3Hthymidine incorporation in cultured sinusoidal endothelial cells from rats. J Hepatol 1999;31:284–92.
  29. 29.Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982;83:1183–90.
  30. 30.Reynell PC. Portal hypertension in the rat. Br J Exp 1952; Pathol 33: 19-24.
  31. 31.Sakhuja P , Wanless I, Rizvi MR, Gondal R, Sarin SK. Liver histology in a rabbit model of E. coli induced non-cirrhotic portal hypertension. Modern Pathology 2006; 19 (suppl 3): 136
  32. 32.Santra A, Das Gupta J, De BK, Roy B, Guha Mazumder DN. Hepatic manifestations in chronic arsenic toxicity. Ind J Gastroenterol 1999; 18:152–155.
  33. 33.Sugita S, Ohnishi K, Saito M, Okuda K. Splanchinc hemodynamics in portal hypertensive dogs with portal fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol 1987; 252: G748–54.
  34. 34.Villeneuve JP, Huet PM, Joly JG, Marleau D, Cote J, Legare A, Lafortune M, Lavoie P, Viallet A. Idiopathic portal hypertension. Am J Med 1976 Oct;61(4):459-64.
  35. 35.Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portalhypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-G57
  36. 36.W. Laleman, I. Vander Elst, M. Zeegers, R. Servaes, L. Libbrecht, T. Roskams, J. Fevery and F. Nevens. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited European Journal of Clinical Investigation 2006; 36, 242-249
  37. 37.Wanless IR (1987) On the pathogenesis of noncirrhotic portal hypertension. In: Boyer JL, Bianchi L (eds). Liver cirrhosis: Proceedings of the VII international congress of liver diseases (Falk Symoposium No. 44) MTP Press, London, pp 293-311
  38. 38.Yamana H, Yatsuka K, Kakegawa T. Experimental production of portal hypertension in dogs by a whole liver compression. Gastroenterol Jpn 1983; 18(2):119-27. Non-Cirrhotic Portal Hypertension, Moattar R Rizvi 70
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access